Global Blood Therapeutics Stock Price - GBT

0.00 (0.0%)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Global Blood Therapeutics Inc GBT NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.95 -1.83% 51.09 49.03 52.49 51.53 52.04 16:30:00
Bid Price Ask Price Spread Spread % News
49.00 56.45 7.45 13.2% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
9,175 747,994 $ 50.56 $ 37,821,497 1,054,902 39.95 - 87.54
Last Trade Time Type Quantity Stock Price Currency
16:04:07 formt 314 $ 51.09 USD

Global Blood Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 3.11B 60.83M $ -174.19M -4.56 - 59.01M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Global Blood Therapeutics News

Loading Messages....

Latest GBT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical GBT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week47.7657.168646.6551.35957,2033.336.97%
1 Month65.0868.5239.9551.801,153,783-13.99-21.5%
3 Months79.1387.5439.9564.93967,888-28.04-35.44%
6 Months49.6387.5439.9564.071,028,6681.462.94%
1 Year54.1187.5439.9559.96924,386-3.02-5.58%
3 Years36.7087.5424.02547.38956,43914.3939.21%
5 Years34.6587.5412.2442.05818,52316.4447.45%

Global Blood Therapeutics Description

Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.

Your Recent History
Global Blo..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.